2. Disease Areas
  3. Metabolic or Endocrine Disease
  4. Mineral Metabolism
  5. Osteoporosis
  6. FR 78844

FR 78844 is an orally active bone resorption inhibitor. FR 78844 attenuates metaphyseal bone mineral density decreases in Streptozotocin (HY-13753)-induced diabetic rats, and Heparin (HY-17567A)-induced osteopenia, but does not affect vitamin D-deficient rat bone loss. FR 78844 can be used for the research of osteopenia.

For research use only. We do not sell to patients.

FR 78844

FR 78844 Chemical Structure

CAS No. : 112856-39-0

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

FR 78844 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

FR 78844 is an orally active bone resorption inhibitor. FR 78844 attenuates metaphyseal bone mineral density decreases in Streptozotocin (HY-13753)-induced diabetic rats, and Heparin (HY-17567A)-induced osteopenia, but does not affect vitamin D-deficient rat bone loss. FR 78844 can be used for the research of osteopenia[1][2].

In Vitro

FR 78844 potently inhibits PTH-induced calcium release from rat calvaria in vitro with an IC50 of 4.4 × 10-7 M[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

FR 78844 Related Antibodies
In Vivo

FR 78844 (1-100 mg/kg; p.o.; 5 days a week; 4 weeks) significantly attenuates Streptozotocin-induced osteopenic bone loss in rats[1].
FR 78844 (1-100 mg/kg; p.o.; 5 days a week; 4 weeks) significantly attenuates ovariectomy-induced osteopenic bone loss in rats[1].
FR 78844 (1-100 mg/kg; p.o.; 5 days a week; 4 weeks) does not attenuate vitamin D deficiency-induced osteopenic bone loss in rats[1].
FR 78844 (1-100 mg/kg; p.o.; 5 days a week; 4 weeks) dose-dependently attenuates Heparin-induced osteopenia in rats[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar rats (9-week-old female; Streptozotocin (STZ)-induced diabetic model)[1]
Dosage: 1; 10; 100 mg/kg
Administration: p.o.; 5 days a week; 4 weeks
Result: Attenuated the decrease in femur metaphyseal bone mineral density by 66% at 100 mg/kg dose compared to vehicle-treated STZ rats.
Did not produce a significant effect at 1 mg/kg and 10 mg/kg doses.
Animal Model: Wistar rats (9-week-old female; ovariectomized model)[1]
Dosage: 1; 10; 100 mg/kg
Administration: p.o.; 5 days a week; 4 weeks
Result: Attenuated the decrease in femur metaphyseal bone mineral density by 81% at 100 mg/kg dose compared to vehicle-treated ovariectomized rats.
Did not produce a significant effect at 1 mg/kg and 10 mg/kg doses.
Animal Model: Wistar rats (4-week-old female; vitamin D-deficient model)[1]
Dosage: 1; 10; 100 mg/kg
Administration: p.o.; 5 days a week; 4 weeks
Result: Did not produce a significant effect on femur metaphyseal bone mineral density at any tested dose compared to vehicle-treated vitamin D-deficient rats.
Animal Model: Wistar rats (female, 9 weeks old, osteopenia induced by Heparin sodium 2000 U/kg·day subcutaneously 5 days a week for 4 weeks)[2]
Dosage: 1; 10; 100 mg/kg
Administration: p.o.; 5 days a week; 4 weeks
Result: Attenuated the heparin-induced decrease in metaphyseal bone mineral density in a dose-dependent manner.
Produced a significant increase in metaphyseal bone mineral density at 100 mg/kg compared to the vehicle-treated heparinized group.
Showed a significant improvement in metaphyseal bone mineral density at 10 mg/kg relative to the vehicle group.
Molecular Weight

355.15

Formula

C8H9NNa2O6P2S
CAS No.
SMILES

S=C(NC1=CC=CC=C1)C(P(O)(O)=O)P(O[Na])(O[Na])=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

FR 78844 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

FR 78844112856-39-0FR78844FR-78844Othersstreptozotocin-induced diabetic ratsovariectomized ratsbone resorptionvitamin D-deficient ratsfemale Wistar ratsheparin-induced osteopeniaPTHcalcium releaserat calvariametaphyseal bone mineral densityInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
FR 78844
Cat. No.:
HY-122075
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.